Early-life programming is defined by the adaptive changes made by the fetus in response to an adverse in utero environment. Infantile hemangioma (IH), a vascular anomaly, is the most common tumor of infancy. Here we take IH as the tumor model to propose the stem cell teratogenic hypothesis of tumorigenesis and the potential involvement of the immune system.
Objectives:
Teratogenic agents include chemicals, heavy metals, pathogens, and ionizing radiation. To investigate the etiology and pathogenesis of IH, we hypothesized that they result from a teratogenic mechanism. Immature, incompletely differentiated, dysregulated progenitor cells (multipotential stem cells) are arrested in development with vasculogenic, angiogenic, and tumorigenic potential due to exposure to teratogenic agents such as extrinsic factors that disrupt intrinsic factors via molecular mimicry. During the critical period of immunological tolerance, environmental exposure to immunotoxic agents may harness the teratogenic potential in the developing embryo or fetus and modify the early-life programming algorithm by altering normal fetal development, causing malformations, and inducing tumorigenesis. Specifically, exposure to environmental agents may interfere with physiological signaling pathways and contribute to the generation of IH, by several mechanisms.
Discussion:
An adverse in utero environment no longer serves as a sustainable environment for proper embryogenesis and normal development. Targeted disruption of stem cells by extrinsic factors can alter the genetic program.
Conclusions:
This article offers new perspectives to stimulate discussion, explore novel experimental approaches (such as immunotoxicity/vasculotoxicity assays and novel isogenic models), and to address the questions raised to convert the hypotheses into nontoxic, noninvasive treatments.
Get full access to this article
View all access options for this article.
References
1.
PackGT, MillerTR. Hemangiomas: Classification, diagnosis and treatment. Angiology, 1950; 1:405–426.
2.
ZaremHA, EdgertonMT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg, 1967; 39:76–83.
3.
MullikenJB, GlowackiJ. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg, 1982; 69:412–422.
Gonzalez-CrussiF, Reyes-MugicaM. Cellular hemangiomas (“hemangioendotheliomas”) in infants. Light microscopic, immunohistochemical, and ultrastructural observations. Am J Surg Pathol, 1991; 15:769–778.
6.
EnjolrasO, MullikenJB. The current management of vascular birthmarks. Pediatr Dermatol, 1993; 10:311–313.
7.
FishmanSJ, MullikenJB. Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am, 1993; 40:1177–1200.
8.
SmollerBR, ApfelbergDB. Infantile (juvenile) capillary hemangioma: A tumor of heterogeneous cellular elements. J Cutan Pathol, 1993; 20:330–336.
9.
BurtonBK, SchulzCJ, AngleB, BurdLI. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn, 1995; 15:209–214.
10.
CheungD, WarmanM, MullikenJ. Hemangioma in twins. Ann Plast Surg, 1997; 38:269–274.
11.
BielenbergDR, BucanaCD, SanchezR, MullikenJB, FolkmanJ, FidlerIJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol, 1999; 14:401–408.
12.
DroletBA, EsterlyNB, FriedenIJ. Hemangiomas in children. N Engl J Med, 1999; 341:173–181.
13.
HuangSA, TuHM, HarneyJW, et al.Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med, 2000; 343:185–189.
NorthPE, WanerM, MizerackiA, MihmMCJr. GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol, 2000; 31:11–22.
16.
TanST, HasanQ, VelickovicM, RügerBM, DavisRPF, DavisPF. A novel in vitro human model of hemangioma. Mod Pathol, 2000; 13:92–99.
17.
BoyeE, YuY, ParanyaG, MullikenJB, OlsenBR, BischoffJ. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest, 2001; 107:745–752.
18.
NorthPE, WanerM, MizerackiA, et al.A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol, 2001; 137:559–570.
19.
ChillerKG, PassaroD, FriedenIJ. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol, 2002; 138:1567–1576.
20.
NorthPE, WanerM, BrodskyMC. Are infantile hemangiomas of placental origin?. Ophthalmology, 2002; 109:633–634.
21.
RitterMR, DorrellMI, EdmondsJ, FriedlanderSF, FriedlanderM. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A, 2002; 99:7455–7460.
22.
WalterJW, NorthPE, WanerM, et al.Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer, 2002; 33:295–303.
23.
KleinmanME, TepperOM, CaplaJM, et al.Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol, 2003; 1:301–307.
24.
RitterMR, MorenoSK, DorrellMI, et al.Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: A possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol, 2003; 1:291–299.
25.
DadrasSS, NorthPE, BertonciniJ, MihmMC, DetmarM. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol, 2004; 17:1068–1079.
26.
NguyenVA, FurhapterC, RomaniN, WeberF, SeppN. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol, 2004; 35:739–744.
27.
YuY, Wylie-SearsJ, BoscoloE, MullikenJ, BischoffJ. Genomic imprinting of IGF2 is maintained in infantile hemangioma despite its high level of expression. Mol Med, 2004; 10:117–123.
BarnesCM, HuangS, KaipainenA, et al.Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A, 2005; 102:19097–19102.
CalicchioML, CollinsT, KozakewichHP. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol, 2009; 174:1638–1649.
GreenbergerS, BischoffJ. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med, 2011; 1:a006460.
45.
XuD, OTM, ShartavaA, et al.Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol, 2011; 4:54.
UihleinLC, LiangMG, MullikenJB. Pathogenesis of infantile hemangiomas. Pediatr Ann, 2012; 41:1–6.
48.
WassefM, BleiF, AdamsD, et al.Vascular anomalies classification: Recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics, 2015; 136:e203–e14.
49.
BleiF, GuariniA. Current workup and therapy of infantile hemangiomas. Clin Dermatol, 2014; 32:459–470.
50.
MullikenJB, EnjolrasO. Congenital hemangiomas and infantile hemangioma: Missing links. J Am Acad Dermatol, 2004; 50:875–882.
FerringerT. Immunohistochemistry in dermatopathology. Arch Pathol Lab Med, 2015; 139:83–105.
53.
TakataK, HiranoH, KasaharaM. Transport of glucose across the blood-tissue barriers. Int Rev Cytol, 1997; 172:1–53.
54.
UhlenM, FagerbergL, HallstromBM, et al.Proteomics. Tissue-based map of the human proteome. Science, 2015; 347:1260419.
55.
AhrensWA, RidenourRV, 3rd, CaronBL, MillerDV, FolpeAL. GLUT-1 expression in mesenchymal tumors: An immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol, 2008; 39:1519–1526.
56.
Leon-VillapalosJ, WolfeK, KangesuL. GLUT-1: An extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br J Plast Surg, 2005; 58:348–352.
57.
PicardA, BoscoloE, KhanZA, et al.IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma. Pediatr Res, 2008; 63:263–267.
58.
HarbiS, WangR, GregoryM, et al.Infantile hemangioma originates from a dysregulated but not fully transformed multipotent stem cell. Sci Rep, 2016; 6:35811.
59.
BautchVL. Stem cells and the vasculature. Nat Med, 2011; 17:1437–1443.
60.
SmoliarE, SmoliarA, SorkinL, BelkinV. Microcirculatory bed of the human trigeminal nerve. Anat Rec, 1998; 250:245–249.
61.
FriedenIJ, ReeseV, CohenD. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol, 1996; 132:307–311.
62.
SoltaniAM, ReinischJF. Algorithmic approach to the management of hemangiomas. J Craniofac Surg, 2011; 22:585–588.
63.
StrubGM, KirshAL, WhippleME, et al.Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. JCI Insight, 2016; 1:e88856.
ShackletonM, QuintanaE, FearonER, MorrisonSJ. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell, 2009; 138:822–829.
66.
QuintanaE, ShackletonM, SabelMS, FullenDR, JohnsonTM, MorrisonSJ. Efficient tumour formation by single human melanoma cells. Nature, 2008; 456:593–598.
67.
RamirezJ, Gerbal-ChaloinS, MilhavetO, et al.Benchmarking human pluripotent stem cell markers during differentiation into the three germ layers unveils a striking heterogeneity: All markers are not equal. Stem Cells, 2011; 29:1469–1474.
68.
VisvaderJE, LindemanGJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell, 2012; 10:717–728.
69.
LoK, MihmM, FayA. Current theories on the pathogenesis of infantile hemangioma. Semin Ophthalmol, 2009; 24:172–177.
70.
MihmMC, NelsonJS. Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol, 2010; 37:83–87.
71.
SilversteinAM. Ontogeny of the immune response. Science, 1964; 144:1423–1428.
72.
HerzenbergLA, HerzenbergLA. Toward a layered immune system. Cell, 1989; 59:953–954.
73.
MoldJE, McCuneJM. Immunological tolerance during fetal development: From mouse to man. In: AltFW, ed. Advances in immunology. Vol 115. Academic Press; 2012:73–111. 10.1016/B978-0-12-394299-9.00003–5.
74.
MoldJE, VenkatasubrahmanyamS, BurtTD, et al.Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science, 2010; 330:1695–1699.
75.
ManginoM, RoedererM, BeddallMH, NestleFO, SpectorTD. Innate and adaptive immune traits are differentially affected by genetic and environmental factors. Nat Commun, 2017; 8:13850.
76.
RoedererM, QuayeL, ManginoM, et al.The genetic architecture of the human immune system: A bioresource for autoimmunity and disease pathogenesis. Cell, 2015; 161:387–403.
77.
ZhaoH, OzenM, WongRJ, StevensonDK. Heme oxygenase-1 in pregnancy and cancer: Similarities in cellular invasion, cytoprotection, angiogenesis, and immunomodulation. Front Pharmacol, 2015; 5:295.
78.
JoyceJA, FearonDT. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015; 348:74–80.
79.
Gilbert-BarnessE. Teratogenic causes of malformations. Ann Clin Lab Sci, 2010; 40:99–114.
NeedlemanHL. The relationship between prenatal exposure to lead and congenital anomalies. JAMA, 1984; 251:2956.
82.
MartinMB, ReiterR, PhamT, et al.Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology, 2003; 144:2425–2436.
83.
Elongi MoyeneJP, ScheersH, Tandu-UmbaB, et al.Preeclampsia and toxic metals: A case-control study in kinshasa, DR congo. Environ Health, 2016; 15:48.
84.
Hemangioma Investigator Group, HaggstromAN, DroletBA, et al.Prospective study of infantile hemangiomas: Demographic, prenatal, and perinatal characteristics. J Pediatr, 2007; 150:291–294.
85.
IuchiS, KuldellN. Zinc finger proteins: From atomic contact to cellular function. New York: Springer; 2005. 10.1007/b139055.
86.
DijkeP, GoumansM, PardaliE. Endoglin in angiogenesis and vascular diseases. Angiogenesis, 2008; 11:79–89.
87.
LevineRJ, LamC, QianC, et al.Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med, 2006; 355:992–1005.
88.
LancrinC, SroczynskaP, StephensonC, AllenT, KouskoffV, LacaudG. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature, 2009; 457:892–895.
XiongJ. Molecular and developmental biology of the hemangioblast. Dev Dyn, 2008; 237:1218–1231.
91.
PerlingeiroRCR. Endoglin is required for hemangioblast and early hematopoietic development. Development, 2007; 134:3041–3048.
92.
ParkC, MaYD, ChoiK. Evidence for the hemangioblast. Exp Hematol, 2005; 33:965–970.
93.
HuberTL, KouskoffV, FehlingHJ, PalisJ, KellerG. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature, 2004; 432:625–630.
94.
BorgesL, IacovinoM, Koyano-NakagawaN, et al.Expression levels of endoglin distinctively identify hematopoietic and endothelial progeny at different stages of yolk sac hematopoiesis. Stem Cells, 2013; 31:1893–1901.
95.
BaikJ, BorgesL, MagliA, ThatavaT, PerlingeiroRCR. Effect of endoglin overexpression during embryoid body development. Exp Hematol, 2012; 40:837–846.
96.
BorgesL, IacovinoM, MayerhoferT, et al.A critical role for endoglin in the emergence of blood during embryonic development. Blood, 2012; 119:5417–5428.
97.
YamaguchiTP, DumontDJ, ConlonRA, BreitmanML, RossantJ. Flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development, 1993; 118:489–498.
98.
AkhurstRJ. Taking thalidomide out of rehab. Nat Med, 2010; 16:370–372.
99.
ArthurHM, UreJ, SmithAJH, et al.Endoglin, an ancillary TGFß receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol, 2000; 217:42–53.
100.
BarbaraNP, WranaJL, LetarteM. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem, 1999; 274:584–594.
101.
BotellaLM, Sanchez-ElsnerT, Sanz-RodriguezF, et al.Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: Their potential role in the response to vascular injury. Blood, 2002; 100:4001–4010.
102.
BourdeauA, DumontDJ, LetarteM. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest, 1999; 104:1343–1351.
103.
JonkerL, ArthurHM. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev, 2002; 110:193–196.
Sanchez-ElsnerT, BotellaLM, VelascoB, LangaC, BernabeuC. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem, 2002; 277:43799–43808.
106.
WaraAK, FooS, CroceK, et al.TGF-1 signaling and kruppel-like factor 10 regulate bone marrow-derived proangiogenic cell differentiation, function, and neovascularization. Blood, 2011; 118:6450–6460.
107.
DarbrePD. Metalloestrogens: An emerging class of inorganic xenoestrogens with potential to add to the oestrogenic burden of the human breast. J Appl Toxicol, 2006; 26:191–197.
108.
Ansar AhmedS. The immune system as a potential target for environmental estrogens (endocrine disrupters): A new emerging field. Toxicology, 2000; 150:191–206.
109.
KleinmanME, GreivesMR, ChurginSS, et al.Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol, 2007; 27(12):2664–2670.
110.
VenkovCD, RankinAB, VaughanDE. Identification of authentic estrogen receptor in cultured endothelial cells: A potential mechanism for steroid hormone regulation of endothelial function. Circulation, 1996; 94:727–733.
111.
PittmanKM, LoskenHW, KleinmanME, et al.No evidence for Maternal–Fetal microchimerism in infantile hemangioma: A molecular genetic investigation. J Invest Dermatol, 2006; 126:2533–2538.
112.
ReynoldsRM. Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis—2012 curt richter award winner. Psychoneuroendocrinology, 2013; 38:1–11.
113.
HarrisA, SecklJ. Glucocorticoids, prenatal stress and the programming of disease. Horm Behav, 2011; 59:279–289.
114.
WeissG. Endocrinology of parturition. J Clin Endocrinol Metab, 2000; 85:4421–4425.
115.
SoloffMS, AlexandrovaM, FernstromMJ. Oxytocin receptors: Triggers for parturition and lactation?. Science, 1979; 204:1313–1315.
116.
Diamanti-KandarakisE, BourguignonJ-, GiudiceLC, et al.Endocrine-disrupting chemicals: An endocrine society scientific statement. Endocr Rev, 2009; 30:293–342.
117.
HahnT. Placental glucose transporter expression is regulated by glucocorticoids. J Clin Endocrinol Metab, 1999; 84:1445–1452.
118.
SunL, GoffLA, TrapnellC, et al.Long noncoding RNAs regulate adipogenesis. Proc Natl Acad Sci U S A, 2013; 110:3387–3392.
119.
RoachEE, ChakrabartiR, ParkNI, et al.Intrinsic regulation of hemangioma involution by platelet-derived growth factor. Cell Death Dis, 2012; 3:e328.
120.
WongA, HardyKL, KitajewskiAM, ShawberCJ, KitajewskiJK, WuJK. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg, 2012; 130:1012–1021.
121.
YamamotoKR. Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet, 1985; 19:209–252.
122.
BagchiMK. Steroid hormone receptor family: Mechanisms of action. In: HenryHL, NormanAW, eds. Encyclopedia of hormones. New York: Academic Press; 2003:403–410. 10.1016/B0-12-341103-3/00275-8.
123.
KorashyHM, El-KadiAOS. Regulatory mechanisms modulating the expression of cytochrome P450 1A1 gene by heavy metals. Toxicol Sci, 2005; 88:39–51.
124.
RiessML, HalmJK. Lead poisoning in an adult: Lead mobilization by pregnancy?. J Gen Intern Med, 2007; 22:1212–1215.
125.
WeisskopfMG, WeuveJ, NieH, et al.Association of cumulative lead exposure with parkinson's disease. Environ Health Perspect, 2010; 118:1609–1613.
126.
KoppRS, KumbartskiM, HarthV, BrüningT, KäfferleinHU. Partition of metals in the maternal/fetal unit and lead-associated decreases of fetal iron and manganese: An observational biomonitoring approach. Arch Toxicol, 2012; 86:1571–1581.
BetzAG. Have you seen your mother, baby…. Science, 2010; 330:1635–1636.
132.
LigamP, ManuelpillaiU, WallaceEM, WalkerD. Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: Implications for role of the kynurenine pathway in pregnancy. Placenta, 2005; 26:498–504.
133.
GollwitzerES, MarslandBJ. Impact of early-life exposures on immune maturation and susceptibility to disease. Trends Immunol, 2015; 36:684–696.
134.
EdrisB, WeiskopfK, VolkmerAK, et al.Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A, 2012; 109:6656–6661.
135.
KimD, WangJ, WillinghamSB, MartinR, WernigG, WeissmanIL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia, 2012; 26:2538–2545.
136.
WillinghamSB, VolkmerJ-, GentlesAJ, et al.The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors [medical sciences]. Proc Natl Acad Sci, 2012; 109:6662–6667.
137.
WeissmanI. Stem cell therapies could change medicine… if they get the chance. Cell Stem Cell, 2012; 10:663–665.
138.
BeavisPA, StaggJ, DarcyPK, SmythMJ. CD73: A potent suppressor of antitumor immune responses. Trends Immunol, 2012; 35:231–237.
139.
SpychalaJ. Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin Cancer Res, 2004; 10:708–717.
140.
StaggJ, SmythMJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010; 29:5346–5358.
141.
EbadiM, IversenPL. Metallothionein in carcinogenesis and cancer chemotherapy. Gen Pharmacol, 1994; 25:1297–1310.
CoyleP, PhilcoxJC, CareyLC, RofeAM. Metallothionein: The multipurpose protein. Cell Mol Life Sci, 2002; 59:627–647.
144.
HabelN, HamidoucheZ, GiraultI, et al.Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cell Death Dis, 2013; 4:e874.
145.
RohwedelJ, GuanK, HegertC, WobusAM. Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: Present state and future prospects. Toxicol In Vitro, 2001; 15:741–753.
146.
HoogheRJ, OomsD. Use of the fluorescence-activated cell sorter (FACS) for in vitro assays of developmental toxicity. Toxicol In Vitro, 1995; 9:349–354.
147.
ShaoJ, BergerLF, HendriksenPJM, PeijnenburgAACM, LoverenH, VolgerOL. Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol, 2013; 88:673–689.
148.
PrindullG. Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis. Stem Cell Rev, 2005; 1:277–284.
149.
CozzioA, PassegueE, AytonPM, KarsunkyH, ClearyML, WeissmanIL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev, 2003; 17:3029–3035.
150.
LarsonRA, LeBeauMM, VardimanJW, RowleyJD. Myeloid leukemia after hematotoxins. Environ Health Perspect, 1996; 104Suppl 6:1303–1307.
151.
NagaiF, HiyoshiY, SugimachiK, TamuraH. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull, 2002; 25:383–385.
152.
PoulsenCB, BorupR, BorregaardN, NielsenFC, MollerMB, RalfkiaerE. Prognostic significance of metallothionein in B-cell lymphomas. Blood, 2006; 108:3514–3519.
153.
GüntherV, LindertU, SchaffnerW. The taste of heavy metals: Gene regulation by MTF-1. Biochim Biophys Acta, 2012; 1823:1416–1425.
154.
RadtkeF, HeuchelR, GeorgievO, et al.Cloned transcription factor MTF-1 activates the mouse metallothionein I promoter. EMBO J, 1993; 12:1355–1362.
155.
WarnkeRA, LinkMP. Identification and significance of cell markers in leukemia and lymphoma. Annu Rev Med, 1983; 34:117.
156.
GodwinHA. The biological chemistry of lead. Curr Opin Chem Biol, 2001; 5:223–227.
157.
PayneJC, ter HorstMA, GodwinHA. Lead fingers: Pb2+Binding to structural zinc-binding domains determined directly by monitoring lead-thiolate charge-transfer bands. J Am Chem Soc, 1999; 121:6850–6855.
158.
BellingerDC. Lead contamination in flint—An abject failure to protect public health. N Engl J Med, 2016; 374: 1101–1103.
159.
CaseyJA, SavitzDA, RasmussenSG, et al.Unconventional natural gas development and birth outcomes in pennsylvania, USA. Epidemiology, 2016; 27:163–172.
NaeyeR. Disorders of the placenta, fetus, and neonate: Diagnosis and clinical significance. St Louis (MO): Mosby Year Book; 1992.
162.
BaldwinV. Book review. N Engl J Med, 1992; 327:1958–1959.
163.
MundenA, ButschekR, TomWL, et al.Prospective study of infantile haemangiomas: Incidence, clinical characteristics and association with placental anomalies. Br J Dermatol, 2014; 170:907–913.
164.
WinnVD, Haimov-KochmanR, PaquetAC, et al.Gene expression profiling of the human maternal-fetal interface reveals dramatic changes between midgestation and term. Endocrinology, 2007; 148:1059–1079.
